X
[{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$0.2 million","newsHeadline":"CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"WPD Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
CNS Pharmaceuticals has entered into an agreement with WPD Pharmaceuticals Inc for the development of several preclinical drug candidates including WP1122.
Lead Product(s):
WP1122
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
CNS Pharmaceuticals
Deal Size: $1.0 million
Upfront Cash: $0.2 million
Deal Type: Agreement
March 23, 2020